Improving Health and Cancer Services in Low-Resource Countries to Attain the Sustainable Development Goals Target 3.4 for Noncommunicable Diseases

INTRODUCTION

In 1999, the WHO first recognized that noncommunicable diseases (NCDs), which consist of cardiovascular disease, cancer, diabetes, and chronic respiratory diseases, were a major health problem. By 2020, it was expected that NCDs would account for 73% of global deaths and 60% of the global burden of disease.¹ In 2012, NCDs were responsible for approximately 38 million deaths per year or 68% of deaths worldwide. For premature deaths in 2012—between age 30 and 70 years—an estimated 52% were a result of NCDs.² In 2015, a total of 47% of premature deaths that were attributable to NCDs occurred in low-resource countries (LRCs), namely, low-income countries (LICs) and lower-middle-income countries (Lo-MICs).³ These premature deaths primarily affect working persons who support a family so that preventing such deaths would have social and economic benefits for LRCs. NCDs have the common preventable risk factors of tobacco use, harmful use of alcohol, unhealthy diet, and physical inactivity, and the WHO has provided advice to assist member states to control these factors.⁴⁻⁶

The United Nations Sustainable Development Goals 2015 to 2030 includes a specific goal for health (Sustainable Development Goal [SDG] 3) with 13 targets, including SDG3.4 for the control and treatment of noncommunicable diseases (NCDs), namely, cardiovascular diseases, cancer, diabetes, and chronic lung disease. There is considerable concern that SDG3.4 may not be achieved. The WHO Best Buys for NCDs has emphasized prevention, and although crucial, it alone will not achieve the 30% reduction in NCDs by 2030. Likewise, a strengthened health system is required as all NCDs are likely to require hospital facilities and community services for optimal management. This is a major problem for low-resource countries (LRCs)—that is, low-income countries and lower-middle-income countries—as most currently have a poorly developed health system, including cancer services, in need of upgrading. This is a result of the extreme poverty of LRCs, where 40% to 80% of the population live on less than USD $1.25 per day, with the average health spending by governments in low-income countries at $110 per person per year. In this article, we outline a comprehensive national cancer services plan for LRCs. Surgery, radiotherapy, and chemotherapy for cancer treatment also require input from other specialties, such as anesthesia, pathology, laboratory medicine, a blood bank, and diagnostic radiology. This will provide a focus for adding additional specialties, including cardiology, respiratory medicine, and psychiatry, to support the management of all NCDs and to contribute to the overall strengthening of the health system. The national cancer services plan for LRCs will require significant funding and input from both in-country and overseas experts in health, cancer, and finance working collaboratively. Success will depend on thoughtful strategic planning and providing the right balance of overseas support and guidance, but ensuring that there is in-country ownership and control of the program is essential.
become involved in a range of goals and targets. Unfortunately, many member states, particularly in LRCs, are unlikely to be able to meet a number of goals and targets, including the SDG3.4 target of 30 by 30.\textsuperscript{8,9} This is a result of several factors, including a lack of government commitment or human and physical resources plus widespread poverty.

The WHO Best Buys—updated 2017—recommends interventions for NCDs based on Appendix 3 of the WHO Global Action Plan for NCDs 2013 to 2020.\textsuperscript{10} The majority of the recommendations are related to prevention rather than hospital care. Whereas prevention is an essential part of the management of NCDs, and even though it may be cost effective, it will take several decades for prevention measures, such as smoking cessation or human papillomavirus vaccination, to have any impact.

For control of cervical cancer, WHO Best Buys has recommended screening for women age 30 to 49 years using visual inspection and acetic acid, Papanicolau test, or human papillomavirus test linked with the timely treatment of precancerous lesions. No mention is made of invasive cervical cancer, including stage I and II, and not just precancerous lesions.\textsuperscript{11,12} It has recently been suggested that stage I and II invasive cervical cancer should be treated by either surgery or radiotherapy with or without chemotherapy.\textsuperscript{3} We would point out that all stages of invasive cervical cancer, including stage I and II, have been effectively managed using external beam radiotherapy and brachytherapy alone since at least the 1950s. However, both surgery or external beam radiotherapy and brachytherapy require a well-developed health system and support from cancer-related specialties.

The WHO Best Buys recommend that new cases of acute myocardial infarction be treated with aspirin, thrombolysis, or percutaneous coronary interventions. These would occur in a hospital with follow-up in primary health care facilities at a 95% coverage rate. Unless health care strengthening is prioritized in LRCs, the SDG Target 3.4 will not be attainable.

All NCDs are likely to require hospital facilities for the management of patients at some stage, particularly when complications develop. Establishing a sustainable health system is therefore essential if the 30 by 30 is to be achieved. In this article, we propose a national cancer services plan (NCS) for LRCs. A comprehensive

Table 1. Estimated Worldwide Cancer Incidence, 2010 to 2030

| World Bank Country Income Group | 2010     | 2030     | Change, % |
|---------------------------------|----------|----------|-----------|
| LICs                            | 631,527  | 1,141,472| 81        |
| Lo-MICs                         | 2,298,066| 3,870,173| 68        |
| LRCs                            | 2,929,593| 5,011,645| 71        |
| Up-MICs                         | 4,986,066| 7,971,873| 60        |
| LMICs                           | 7,915,669| 12,983,518| 64   |
| HICs                            | 5,166,589| 7,112,207| 38        |
| World                           | 13,313,111| 20,095,525| 51      |

NOTE. Data shown are absolute and percentage change in cancer incidence (millions) by income groups, 2010 to 2030.

Abbreviations: HIC, high-income country; LIC, low-income country; LMIC, low- and middle-income country (LRCs and Up-MICs); Lo-MIC, lower-middle-income country; LRC, low-resource country (LICs and Lo-MICs); Up-MIC, upper-middle-income country.

Table 2. Country Income Groups and Health Spending Per Person Per Year

| World Bank Country Income Group (2017) | Mean, USD | Range, USD |
|----------------------------------------|-----------|-----------|
| LIC (< $1,025)                         | 110       | 108-111   |
| Lo-MIC ($1,026-4,035)                  | 265       | 263-268   |
| Up-MIC ($4,036-12,475)                 | 950       | 943-959   |
| HIC (> $12,475)                        | 5,550     | 5,503-5,605|

Abbreviations: HIC, high-income country; LIC, low-income country; Lo-MIC, lower-middle-income country; Up-MIC, upper-middle-income country.
approach with surgery, radiotherapy, and chemotherapy, with involvement of anesthesia, medicine, pathology, diagnostic radiology, and palliative care, is essential for the diagnosis, treatment, and management of cancer. With this structure in place, it will be relatively easy to expand the hospital system to include noncancer specialist services for NCDs, such as, cardiology, diabetes, respiratory medicine, and psychiatry. Therefore, investment in a strong health system that encompasses acute and primary care services is an absolute requirement for any national response for the control of NCDs. We recommend that this change in approach be a priority for member states, particularly in LRCs, to achieve an effective global response to SDG3.4.

**LRCs AND HEALTH**

In 2013, the global population was estimated to be 7.12 billion persons, consisting of 0.85 billion persons in LICs (11.9%), 2.55 billion Lo-MICs (35.8%), 2.45 billion in upper-middle-income countries (34.4%), and 1.27 billion in high-income countries (HICs; 17.8%).13 Although NCDs affect the poorest communities at all levels of society, this article focuses on the 48% of the world population living in LRCs—LICs and Lo-MICs—where poverty is more widespread and health and cancer care is less affordable than in the rest of the world. The predicted overall increase in global cancer incidence between 2010 and 2030 is 51%, and this will be greater in LICs (81%) and Lo-MICs (68%) than in Up-MICs (60%) or HICs14 (38%; Table 1).

Extreme poverty is the main reason for the current lack of health and cancer services in LRCs, where 40% to 80% of the population survive on less than USD $1.25 per day and more than 50% of the population lives in rural areas. Total spending by LRC governments on health is typically less than 5% of the gross domestic product in LRCs15 and averages only $110 per person per year in LICs and $265 in Lo-MICs16 (Table 2). Furthermore, patients and families in LRCs must pay out-of-pocket expenses for health and cancer care, and treatment costs frequently result in catastrophic poverty when spending is greater than 30% of personal annual income. Late presentation of locally advanced and incurable disease is frequently a result of the myths and stigma about cancer and reliance on traditional medicine practices mostly given by untrained health workers, which often result in misdiagnosis and ineffective treatment. Widespread poverty plus a lack of roads and public transport make access to the limited cancer treatment facilities impossible for much of the population. The situation is exacerbated by a lack of education about cancer at all levels of society in LRCs, including government bodies, and the commonly held view that cancer is not curable and results in a painful death.

Surgery17 and radiotherapy18 have been demonstrated to be cost-effective investments in health and cancer services and to provide major social and economic benefits by preventing unnecessary and premature death and disability. This will have a positive impact on the micro- and macroeconomic environment of a country, improve gross domestic product, and help LRCs to climb out of their parlous financial state that has existed for decades.

The Lancet Commission on Global Surgery has drawn attention to the worldwide inequities and deficiencies in surgery and anesthesia.19 Likewise, the Lancet Oncology Commission on Radiotherapy has demonstrated a huge global deficit in radiotherapy, with many LRCs without any radiotherapy at all.18,20 The significant deficit in pathology and laboratory medicine services in low- and middle-income countries was documented in a Lancet series,21 although the lack of pathology has been noted before.22-25 The inadequacy of the surgical workforce,26-28 lack of oncology nursing29 and palliative care services that include morphine,30,31 or the use of falsified or substandard chemotherapy drugs32-34 and lack of access to medications in LRCs have been well documented.35,36

Health system upgrades are needed at several levels by improving primary health care at health posts and nursing stations in rural and remote areas, level 1 hospitals in district towns and level 2 hospitals in regional cities, and major level 3 tertiary hospitals in capital cities.37 Despite the lack of political will and the ability to do so, governments face barriers to improving health care in LRCs that include the cost of buildings, equipment, and technology required; an inability to train medical and paramedical staff and to pay for their subsequent employment; and the cost and reliability of the supply chain for medical consumables. A change in emphasis in the approach to NCDs, particularly in LRCs, is
needed so that a strong health system is available and diagnosis, treatment, and management become a priority. Without adequate hospital and community facilities and adequately trained staff, any improvement in the SDG Target 3.4 is unlikely to occur.

**NCSP FOR LRCs**

Although cancer services in most LRCs are likely to be suboptimal, a large variation exists between and within most countries. For example, there is no radiotherapy available in some LRCs and in others the equipment will have long passed its use-by date and may not be suitable for the treatment of patients, even for palliation.20

A single-model NCSP will not be applicable for all LRCs as the aim for cancer services will also vary according to the wishes of the particular LRC government. We propose a NCSP with cancer centers developed in a coordinated fashion within the LRC to achieve improved patient access to management, diagnosis, and treatment of cancer. This will be a step-wise process over many years and will require a planning process that involves both public and private hospitals. The aim is to establish a national cancer center (NCC) and a network of several regional cancer centers (RCCs).

We recommend that the NCC be a part of a level 3 hospital in major capital city and equivalent to a comprehensive cancer center in an HIC. It should have the complete range of facilities for the diagnosis, management, and treatment of cancer, including surgery and anesthesia, radiotherapy/clinical oncology chemotherapy/hematology, and palliative care. In addition to updating cancer equipment, the NCC would be a part of a hospital that includes cancer support specialties, such as pathology, blood bank, and diagnostic radiology, at the one site. The NCC would be a focus for education and training of medical, paramedical, and administrative staff, and would also be involved in cancer education and prevention, including vaccination programs plus screening, research, and the establishment of a national cancer registry. Using the hospital as a base would make it easier to expand the noncancer specialties to support other NCDs. RCCs would also have a full range of cancer equipment and technology plus cancer support specialties with the main aim of providing treatment closer to home. These facilities would be in well-developed level 1 and 2 hospitals in regional cities and organized in a hub-and-spoke fashion from the NCC with sharing of staff, subspecialization, common treatment protocols, and a multidisciplinary approach to cancer management.

**PLANNING FOR THE NCSP**

Planning for the NCSP would start with an audit of hospital and cancer services within the LRC to determine what is present, what is missing, and what is needed, as well as where the NCC and RCCs should be sited. This would be the most difficult and prolonged period of the NCSP as it would involve discussion and interaction by a multitude of in-country and overseas experts in health, cancer, and finance. The final outcome would undoubtedly be influenced by the existing staff and facilities in the LRC and the funds available for the NCSP project.

In some instances, it may be more realistic to have a series of plans for the phased development of the NCSP, rather than trying to solve the process at once. This will depend on the size of the LRC nation and its population as well as the initial status of health and cancer services. Each LRC will have different requirements for the establishment of the NCSP. Levels of equipment, staffing, and infrastructure of the NCC and RCCs would depend on the finances available and would only be decided after extensive discussions between the national cancer unit (NCU), LRC government, and overseas and local experts.

It is vitally important for the ultimate success of the NCSP to ensure that the LRC government has a strong buy-in, extensive involvement, and a sense of ownership of the project.

Organizations needed for the NCSP:

- An NCU
- A central cancer office (CCO)
- A cancer partnership (CP)
- A cancer fund (CF)

**NCU**

An NCU should be within the LRC to lead and direct the NCSP. An NCU should be established within the ministry of health and funded by the CF. The director would ideally be a respected senior medical administrator or cancer specialist.
The NCU would be the in-country coordinator of the NCSP and would act as a focal point for the cancer activities of the LRC. Heads of government, members of parliament, the ministry of health, treasury, ministry of finance, ministry of education and training, colleges and universities, professional societies and technical organizations, WHO country office, local embassies, the national cancer society, social society, and other experts would interact via the NCU.

The NCU and LRC government would work in close cooperation with the CCO, CF, and CP to ensure that the NCSP achieves its outcomes in a timely manner. Initially, the NCU, CCO, and CP would undertake the needs assessment within the LRC as outlined above. This would include details of the buildings, infrastructure, equipment, technology, staffing, and training needed. Access to a stable electricity supply, air conditioning, clean drinking water, and contracts for maintenance and spare parts is also needed. The cost of overseas experts to visit the LRC for education and training would also need to be included.

The NCU and CCO would determine an estimate of the total cost and a timeframe for the establishment of the NCC. This would be forwarded to the CCO for review and approval by the grants committee and CCO Board. Funding would be restricted to intervals of 2 years and would be subject to a performance-based assessment so that only effective and successful programs would receive continued funding. The National Cancer Society (NCS) would also work with international banks and other potential funders, such as PricewaterhouseCoopers, KPMG, Rotary International, and the NCU to establish cost-free patient access from outreach clinics to the NCC or RCCs for diagnosis and treatment, and accommodation if needed. The NCU, ministry of health, and NCS should promote cancer education, prevention and early detection measures, screening, a national cancer registry and palliative care facilities. The NCU and CP as well as the ministry of education and training, universities, and colleges would be responsible for the training of professional staff for hospitals and medical specialties as well as an accreditation process for hospitals and staff.

**CCO**

The CCO would be required to assist the NCU with appropriate governance, coordination, and operation of the NCSP. The location of the CCO would ideally be in major capital city alongside international government agencies, such as the WHO in Geneva, Switzerland.

Funded by the CF, staff would include a chief executive officer with an elected board, and selected members of the NCU, a CP, a CF, and a grants committee. Establishing the CCO would require a planning committee of 10 to 12 members from health, cancer, and finance who have experience in LRCs and a willingness to support the overall program. For those from health and cancer backgrounds, this would include senior members of the colleges of surgery, medicine, radiation oncology, pathology, radiology, general practice, and palliative care. A number of experts with global health financing experience would be recruited for the CF.

The planning committee would meet to discuss the feasibility of the NCSP and appoint members of the CCO board, CP, and CF. Likely LRCs for pilot studies of the NCSP would also be selected. During the development of the NCSP, the NCU,

---

**Table 3. Panel 1—Data on HIV/AIDS and Funding**

| Data on HIV/AIDS and Funding |
|-----------------------------|
| New HIV infections decreased from 3 million in 1995 to 2.5 million in 2005 and 1.8 million in 2016 |
| AIDS-related deaths decreased from 1.5 million in 2000 to 1.1 million in 2015 |
| People living with HIV/AIDS increased from 18 million in 1995 to 36.7 million in 2016 |
| People living with HIV accessing ART increased from 2.2 million in 2005 to 20.9 million in 2017 |
| Global spending on HIV/AIDS increased from $16.4 billion in 2000 to $48.9 billion in 2015 or by 8.9% per annum from 2000 to 2013, but by only 0.8% per annum since then (total, $562.6 billion) |
| Cost of ART in 2003 was USD $1,500 per person and decreased to USD $150 per person in 2014 |

Sources of funding include The World Bank; development banks; the Gates Foundation; US foundations; philanthropic endowments; The Global Fund for AIDS, TB, and Malaria; The Presidents Emergency Plan for AIDS Relief; Gavi—the alliance; international nongovernmental organizations; United Nations agencies—WHO, UNICEF, UNFPA, UNAIDS, and PAHO; bilateral development agencies; overseas high-income country governments—United States, United Kingdom, Germany, France, Canada, and Australia.
CCO, CP, CF, and LRC government would be involved and would develop close cooperation to ensure the NCSP meets its commitments and time scales.

**CP**

A CP works in the LRC with the NCU to undertake a needs assessment, followed by infrastructure, installation of equipment, and involvement in the education and training of professional staff. The CP would act as an umbrella organization to bring together in-country and overseas experts from relevant professional colleges, universities, and societies who have experience in the relevant aspects of health and cancer services. CP groups would include surgery and anesthesia, radiotherapy/clinical oncology, medicine, hematology/oncology/blood bank, pathology and laboratory medicine, diagnostic radiology, palliative care, pediatric oncology, and general and oncology nursing. Also included would be paramedical staff for each specialty, such as radiographers, laboratory staff, technicians, medical physicists, biomedical engineers, and information technologists.

Interaction with other medical specialty groups in cardiology, diabetes, and respiratory medicine for NCDs would be developed as part of their association with the NCSP. Also included would be the parallel development of psychiatry, pediatrics, obstetrics, and gynecology plus other specialties needed to support the health aspects of the 2030 Agenda. CP groups would play an essential role in the initial needs assessment by the NCU, COO, and CP to determine the requirements of the NCSP. Members from each specialty would be asked to provide an outline of the equipment required for their specialty to operate at basic, intermediate, and advanced levels. A training program would be for current in-country professional staff, including for the assessment of competency. New professional staff would be involved of in an education program at colleges and universities to ensure that continuing in-country training is developed for the future. For each specialty, this would involve extensive discussion and agreement with relevant overseas experts and in-country members of professional societies, colleges, universities, the NCU, and government.

**CF**

A CF would develop long-term sustainable funding for the NCSP. Establishment of a CF is critical for the success of the NCSP, as without long-term
Funding it will not occur. Funds are needed for the NCU, CCO, CF, and CP and for buildings, infrastructure, equipment, consumables and technology, service and maintenance contracts, and for the training and employment of medical and paramedical professional staff, including hospital and government administrative staff.

A global CF has been proposed and there has been a recent focus on increasing global funding for health. Other methods, such as innovative financing, have also been suggested. Traditional funding sources, such as multinational and local or regional banks, philanthropic organizations, and official development assistance from overseas HICs, are still potential funding sources. The role of private-public partnerships and exploring partnership governance in global health has recently been examined by the National Academies of Sciences, Engineering, and Medicine. Donations from in-country wealthy citizens or companies would increase the sense of ownership of a NCSP. The Mwanza Cancer Project in Tanzania is an example of local initiative. Another is the use of money from tobacco taxation that has supported the BP Koirala Cancer Hospital in Nepal since 1994.

The Global Fund to fight AIDS, Tuberculosis and Malaria, or The Global Fund, has been one of the most successful medical fundraising initiatives over the last two decades and has significantly improved diagnosis, treatment, and outcomes for millions of patients with HIV/AIDS (Table 3). It provides an excellent model for funding a NCSP in LRCs, and an approach similar to that of The Global Fund would be a suitable working model for health and cancer services in LRCs. Our suggestion to expand the donor base to tackle priority health issues in LRCs using cancer services as a focus is not intended to imply any reduction in funding for HIV/AIDS. There has been significant progress with HIV/AIDS through The Global Fund and more funds are needed. However, it is worth noting that cancer results in more deaths worldwide each year than do HIV/AIDS, tuberculosis, and malaria combined.

Funding for global health is increasingly complex and it is essential that the CF group includes members with experience in relevant programs to boost health finances in LRCs. A mechanism to ensure that funding is properly accounted for is also crucial. Funding by the CF would aim to make the NCSP cost free for patients with cancer as part of developing universal health cover for the nation. Otherwise those who live in poverty will not be able to afford any available treatment. Because a sense of ownership by the LRC is important for the success of the NCSP, a contribution by the LRC government to staff salaries, for example, would ensure the long-term viability of the program. Although funding is unlikely to be the same for each LRC, there may be a benefit for a particular LRC to pool official development assistance funds from several embassies for the NCSP.

**TRAINING AND EDUCATION OF PROFESSIONAL STAFF**

Developing training and education is essential to enable the delivery of safe, accurate, and effective treatments in the above disciplines. In view
of the large numbers of different professional staff required, a train-the-trainer practical approach is recommended. Training should take place in-country using the equipment available rather than being done entirely in overseas countries. Training will be needed at several levels for persons who may have worked in health and cancer services in LRCs for many years, but who lack formal training as well as for new recruits into their particular specialties who will require education at an in-country university or college and hands-on practical training.

The composition of the training programs will be decided by the CP and in-country experts in each specialty and will include theoretical and practical training with assessments of competency. Each CP specialty should be expected to provide a complete team of qualified professionals from chosen overseas departments to be responsible for the delivery of the training required for in-country staff in their own specialty at the NCC.

CP groups should be expected to be actively involved in the operation of the new departments from the initial start-up for a period of up to 2 years. This would involve working with in-country staff in a hands-on approach to patient treatment and management to ensure they can work as safe, accurate, and efficient professionals. CP groups would also provide ongoing support after the initial training period via teleconferencing and online support and twinning arrangements.

It is also important that in-country persons are required to undergo continuing professional development after the completion of their initial course of training. The absence of a certificate may make employment overseas more difficult, but the brain drain effect can also be minimized by incentives from the LRC government, such as one that provides hospital housing or wage increases in exchange for undertaking additional training.

**DISCUSSION**

The 2030 Agenda is an ambitious plan that attempts to change the world by improving the well-being of all people and ensuring that no one is left behind. The WHO Global Action Plan for NCDs 2013 to 2020 aims for a 25% reduction in premature deaths from NCDs by 2025 (25 by 25) and the 2030 Agenda has proposed a 30% reduction by 2030 (30 by 30). Neither of these goals are likely to be achieved without significant additional funding and a change in approach that involves a commitment to the development of a strong health system, particularly in LRCs.

WHO has introduced Best Buys as a series of interventions for each of the four key risk factors and the four key diseases areas for NCDs. As stated previously, the Best Buys are essentially prevention measures and will take several decades to affect survival; however, a strong health system is an essential requirement for the management of NCDs and other health-related SDG targets.

Unfortunately, the greatest burden of NCDs falls on the poorest countries that are least likely to be equipped or able to afford the control of NCDs. We therefore propose a NCSP that will concentrate on LRCs as a result of the high incidence of premature NCD deaths, widespread poverty, and poorly developed health systems (Table 4). The NCSP will also have a substantial flow-on effect and improve the overall health system that would support the other NCDs and cancer.

The social sector also has an important and often undervalued role to play in the delivery of cancer services, particularly in LRCs. As access to care is a major problem in LRCs, this means supporting the social and financial needs of patients and providing access to care during treatment and palliation. In addition, like HIV/AIDS treatment, cancer treatment needs to be cost free to the population so that the uptake is maximized. Although we have not suggested any particular approach to funding, we have drawn attention to the results of HIV/AIDS funding as an example of what can be achieved.

We also suggest that the NCSP should initially be started as a pilot study in one or two LRCs to properly assess its feasibility before expanding to include other LRCs. The NCSP program will require international collaboration from overseas experts in finance, health, and cancer to support the LRC government in leading the development of the NCSP. Success will depend on strategic planning and providing the right balance of overseas support and guidance to ensure that there is in-country ownership and control of the program. The success of HIV/AIDS treatment has provided a proof of concept of what can be achieved and we urge the global cancer community to take immediate action to end the global inequality in cancer care (Table 5).

**DOI:** https://doi.org/10.1200/JGO.18.00185
Published online on jgo.org on November 30, 2018.
AUTHOR CONTRIBUTIONS

Conception and design: Graeme W. Morgan, Kirsty Foster, Brendan Healy, Vu Huynh
Collection and assembly of data: Graeme W. Morgan, Vu Huynh
Data analysis and interpretation: Graeme W. Morgan, Craig Opie, Vu Huynh
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Graeme W. Morgan
No relationship to disclose
Kirsty Foster
No relationship to disclose
Brendan Healy
Employment: Icon Health (i)
Craig Opie
No relationship to disclose
Vu Huynh
No relationship to disclose

ACKNOWLEDGMENT

During the past 10 years, the authors and a large number of volunteers have attempted to assist in the development of safe, accurate, and effective radiotherapy in Papua New Guinea, Vietnam, Nepal, Cambodia, and Myanmar. During these visits, cordial relationships were developed with many medical and paramedical professionals and government officials in these countries. This has provided practical insights into how health and cancer services can be improved in these countries and forms the basis of this article. We thank them for inviting us to visit their countries and express our appreciation of the kindness given to the authors and all volunteers.

Affiliations

Graeme W. Morgan, Kirsty Foster, and Vu Huynh, The University of Sydney; Craig Opie, Royal North Shore Hospital, Sydney, New South Wales; and Brendan Healy, Icon Cancer Group, Brisbane, Queensland, Australia.

REFERENCES

1. World Health Organization: Global strategy for the prevention and control of noncommunicable diseases. apps/who/int/gb/archive/pdf_files/EB105/ee42.pdf
2. World Health Organization: Appendix A: Noncommunicable diseases SDG Target 3.4. World Health Statistics 2016, p 60. Monitoring health for the SDGs. World Health Organization, Geneva, Switzerland. 2016. http://www.who.int/gho/publications/world_health_statistics/2016/EN_WHS2016_Annex_A.pdf?ua=1
3. World Health Organization: Preparation for the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases to be held in 2018. http://apps.who.int/gb/ebwha/pdf_files/EB142/B142_15-en.pdf
4. World Health Organization: WHO Framework Convention on Tobacco Control. Geneva, Switzerland, World Health Organization, 2003
5. World Health Organization: WHO Global Strategy to Reduce the Harmful Use of Alcohol. Geneva, Switzerland, World Health Organization, 2010
6. World Health Organization: WHO Global Strategy on Diet, Physical Activity and Health. Geneva, Switzerland, World Health Organization, 2004. http://www.who.int/dietphysicalactivity/strategy/eb11344/strategy_english_web.pdf
7. World Health Organization: Transforming our world: The 2030 Agenda for Sustainable Development. https://sustainabledevelopment.un.org/post2015/transformingourworld
8. United Nations: Progress on the prevention and control of non-communicable diseases. https://digitallibrary.un.org/record/1474584?ln=en
9. Nishtar S, Niinistö S, Sirisena M, et al: Time to deliver: Report of the WHO Independent High-Level Commission on NCDs. Lancet 392:245-252, 2018
10. World Health Organization: ‘Best Buys’ and other recommended interventions for the prevention and control of non-communicable diseases. Updated 2017 Appendix 3 of the Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. http://www.who.int/ncds/management/WHO_Appendix_BestBuys.pdf
11. World Health Organization: Comprehensive Cervical Cancer Control: A Guide to Essential Practice. Geneva, Switzerland, World Health Organization, 2006

12. World Health Organization: Comprehensive Cervical Cancer Control: A Guide to Essential Practice, 2. World Health Organization, Geneva, Switzerland. 2014

13. World Health Organization: World Health Statistics 2015: Part II. Global Health Indicators, Table 9. World Health Organization, Geneva, Switzerland. 2016, p 158

14. Bloom DE, Cafiero ET, Jane-Llopis E, et al: The global economic burden of non-communicable diseases. World Economic Forum, 2011, pp 18-19 [Internet pdf]. http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf

15. World Health Organization: World Health Statistics 2015: Part II. Global Health Indicators, Table 7. World Health Organization, Geneva, Switzerland. 2016, p 134

16. Institute for Health Metrics and Evaluation: Financing Global Health 2017: Funding global health coverage and the unfinished HIV/AIDS agenda. http://www.healthdata.org/policy-report/financing-global-health-2017

17. Chao TE, Sharma K, Mandigo M, et al: Cost-effectiveness of surgery and its policy implications for global health: A systematic review and analysis. Lancet Glob Health 2:e334-e345, 2014

18. Atun R, Jaffray DA, Barton MB, et al: Expanding global access to radiotherapy. Lancet Oncol 16:1153-1186, 2015

19. Meara JG, Leather AJM, Hagander L, et al: Global Surgery 2030: Evidence and solutions for achieving health, welfare, and economic development. Lancet 386:569-624, 2015

20. Elmore SN, Sethi RV, Kavuma A, et al: Broken machines or broken systems: The road to meaningful global radiotherapy access. J Glob Oncol, 2017

21. Wilson ML, Fleming KA, Kuti MA, et al: Access to pathology and laboratory medicine services: A crucial gap. Lancet 391:1927-1938, 2018

22. Schroeder LF, Amukele T: Medical laboratories in sub-Saharan Africa that meet international quality standards. Am J Clin Pathol 141:791-795, 2014

23. Fleming KA, Naidoo M, Wilson M, et al: An essential pathology package for low- and middle-income countries. Am J Clin Pathol 147:15-32, 2017

24. Carlson JW, Lyon E, Walton D, et al: Partners in pathology: A collaborative model to bring pathology to resource poor settings. Am J Surg Pathol 34:118-123, 2010

25. Mpunga T, Tapela N, Hedt-Gauthier BL, et al: Diagnosis of cancer in rural Rwanda: Early outcomes of a phased approach to implement anatomic pathology services in resource-limited settings. Am J Clin Pathol 142:541-545, 2014

26. Hoyler M, Finlayson SRG, McClain CD, et al: Shortage of doctors, shortage of data: A review of the global surgery, obstetrics, and anesthesia workforce literature. World J Surg 38:269-280, 2014

27. Holmer H, Lantz A, Kunjumen T, et al: Global distribution of surgeons, anaesthesiologists, and obstetricians. Lancet Glob Health 3:S9-S11, 2015 (suppl 2)

28. Sullivan R, Alatise OI, Anderson BO, et al: Global cancer surgery: Delivering safe, affordable, and timely cancer surgery. Lancet Oncol 16:1193-1224, 2015

29. So WKW, Cummings GG, Ayala de Calvo LE, et al: Enhancement of oncology nursing education in low- and middle-income countries: Challenges and strategies. J Cancer Policy 8:10-16, 2016

30. Cherny NI, Cleary J, Scholten W et al. The Global Opioid Policy Initiative (GOPI) project to evaluate the availability and accessibility of opioids for the management of cancer pain in Africa, Asia, Latin America and the Caribbean and the Middle East: Introduction and methodology. Ann Oncol 11:xi7-13, 2013 (suppl)

31. Union for International Cancer Control: Global Access to Pain Relief Initiative (GAPRI). www.uicc.org/sites/main/files/atoms/files/UICC_OnePager_Gapri.pdf

10 jgo.org JGO – Journal of Global Oncology
32. Institute of Medicine: Countering the problem of falsified and substandard drugs. Washington, DC, The National Academies Press, 2013
33. Attaran A, Barry D, Basheer S, et al: How to achieve international action on falsified and substandard medicines. BMJ 345:e7381, 2012
34. World Health Organization: Provisional agenda item 17.1. Substandard/spurious/falsely labelled/ falsified/counterfeit medical products. Sixty-Sixth World Health Assembly, Geneva, Switzerland, May 23, 2017
35. Newton PN, Tabernero P, Dwivedi P, et al: Falsified medicines in Africa: All talk, no action. Lancet Glob Health 2:e509-e510, 2014
36. World Health Organization: Provisional agenda item 11.5. Addressing the global shortage of, and access to, medicines and vaccines. Seventy-First World Health Assembly, Geneva, Switzerland, March 19, 2018
37. McCord C, Ozgediz D, Beard JH, et al: General surgical emergencies: Table 4.1: Definition of levels of hospital care, in Debas HT (ed): Essential Surgery. Disease Control Priorities, Volume 1 (ed 3). World Bank, Washington, DC, 2015, p 62
38. Cavalli F, Atun R: Towards a global cancer fund. Lancet Oncol 16:133-134, 2015
39. Atun R, Knaul FM, Akachi Y, et al: Innovative financing for health: What is truly innovative? Lancet 380:2044-2049, 2012
40. National Academies of Sciences, Engineering, and Medicine: The Role of Public-Private Partnerships in Health Systems Strengthening: Workshop Summary. Washington, DC, The National Academies Press, 2016. http://nap.edu/21861
41. National Academies of Sciences, Engineering, and Medicine: Engaging the Private Sector and Developing Partnerships to Advance Health and the Sustainable Development Goals. Proceedings of a Workshop Series. Washington, DC, The National Academies Press, 2017. http://nap.edu/24744
42. National Academies of Sciences, Engineering, and Medicine: Exploring Partnership Governance in Global Health: Proceedings of a Workshop. Washington, DC, The National Academies Press, 2018. http://nap.edu/25069
43. Amadori D, Serra P, Bucchi L, et al: The Mwanza cancer project. Lancet Oncol 17:146-148, 2016
44. Poore P, Nantulya VM, Mogedal S, et al: The Global Fund to Fight AIDS, Tuberculosis and Malaria. Health Policy Plan 19:52-53, discussion 54-56, 2004
45. UNAIDS: Fact sheet – Latest global and regional statistics and the status of the AIDS epidemic. http://www.unaids.org/en/resources/documents/2018/UNAIDS_FactSheet
46. Lu C, Schneider MT, Gubbins P, et al: Public financing of health in developing countries: A cross-national systematic analysis. Lancet 375:1375-1387, 2010
47. Hazin R, Qaddouri I: Teleoncology: Current and future applications for improving cancer care globally. Lancet Oncol 11:204-210, 2010
48. Dorsey ER, Topol EJ: State of telehealth. N Engl J Med 375:154-161, 2016
49. Ngwa W, Sajo E, Ngoma T, et al: Potential for information and communication technologies to catalyze global collaborations in radiation oncology. Int J Radiat Oncol Biol Phys 91:444-447, 2015